Mpc Therapeutics Announces Completion Of Its Chf 1.5M Seed-Funding Round To Improve Car-T Cancer Therapies.

Jan 11, 2023•almost 3 years ago

Round Type

seed

GenevaTherapeuticsBiotechnologyHealth Care

Investors

Plutus Investment Group

Description

MPC Therapeutics (MPC Tx), a Swiss biotechnology company focused on metabolism and rejuvenation, today announced the closing of its CHF 1.5 million seed-funding round. Funds will serve to advance MPC Tx’s proprietary small molecule towards clinical trials and open new therapeutic applications. The funding round was led by Plutus Investment Group, a London-based family office, and received additional funding from business angels.

Company Information

Company

MPC Therapeutics

Location

Geneva, Alabama, United States

About

At MPC Therapeutics, we are convinced that mitochondria, the small organelles at the core of the cell's metabolism, represent untapped therapeutic targets. Headquartered in Switzerland, our startup is focused on cellular rejuvenation to improve the performance of cell therapies and treat degenerative pathologies. Our novel approach uses proprietary first-in-class small molecules that specifically target mitochondria to trigger metabolic reprogramming. Visit our website for more info.

Related People

2 contacts

Funding Insights

Based on industry data

VC-backed spending patterns